New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Kryxana (Ribociclib 200 mg Film Coated Tablets)

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

It is an anti-cancer, CDK4/6 inhibitor medication used to treat HR-positive, HER2-negative metastatic or advanced breast cancer, often in combination with hormone therapy. It works by slowing or stopping the growth and division of cancer cells.

Kryxana is the brand name for Ribociclib, a  medication developed by Novartis Pharma for breast cancer.

Brand Name: Kryxana
Generic Name: Ribociclib Tablets
Strength: Tablets 200 mg
Manufacturer Name: Novartis India
Packaging: 21 Tablets

Is Kryxana (Ribociclib) officially available/approved in India?

Yes, as of now, Kryxana (Ribociclib) is officially marketed or registered for sale in India. It needs a valid prescription from the Registered Medical Practitioner (RMP). For sourcing facilitation services of Novartis India Pharma products contact us at support@southdelhipharma.comsouthdelhipharma@gmail.com or  you can Call/WhatsApp at 9891296838.

Category
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

What Kryxana is?

Kryxana 200 mg (Ribociclib) is a cyclin-dependent kinase inhibitor, indicated to use with the combination of the aromatase inhibitor to treat HR-Positive and HER2-Negative advanced as well as metastatic breast cancer. This FDA approved medication was developed by Novartis.

What Ribociclib is?

Ribociclib was approved by the U.S. Food and Drug Administration (FDA) in March 2017, and the European Medicines Agency (EMA) in August 2017, for use in combination with an aromatase inhibitor (such as letrozole) to treat HR-positive, HER2-negative advanced or metastatic breast cancers.

Ribociclib, sold under the brand name Kisqali, is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.

Contact for Kryxana (Ribociclib) Tablets

South Delhi Pharma (SDP) is an authorised distributor, supplier, and Carrying & Forwarding Agent (CFA) for Novartis India Pharma products. We serve patients, doctors, B2B partners, and government organisations, ensuring reliable supply and trusted pharmaceutical solutions.

For enquiries, please contact South Delhi Pharma.

Contact Name: Mr. Tarun Garg
Company Name: South Delhi Pharma
Address: 60/4, Yusaf Sarai, Near Indian Oil Corp., New Delhi – 110 016 (India)
Mobile/WhatsApp9891296838.
Emailsupport@southdelhipharma.comsouthdelhipharma@gmail.com

Get Access Kryxana (Ribociclib) For injection In India on request.

Kryxana is avaialble for personal treatment  across India, including Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Aurangabad, Pune, Bengaluru, Hyderabad, Chennai, Visakhapatnam, Coimbatore, and other regions of India.

Note: South Delhi Pharma, act as a facilitation partner and do not manufacture, sell, or distribute pharmaceutical products. All facilitation activities are conducted in accordance with applicable Indian pharmaceutical and trade regulations. 

Related Products